BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 773575)

  • 1. The immune response in human malignant melanoma.
    Mackie RM
    Clin Exp Dermatol; 1976 Mar; 1(1):23-8. PubMed ID: 773575
    [No Abstract]   [Full Text] [Related]  

  • 2. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
    Seigler HF; Shingleton WW; Pickrell KL
    Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunology and cutaneous malignant melanoma.
    Sober AJ
    Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunoreactivity in patients with surgically removed melanoma in the course of BCG vaccination (author's transl)].
    Lochman I; Kyselá T; Machálek J; Lochmanová A; Beska F
    Cesk Dermatol; 1980; 55(6):372-7. PubMed ID: 7460040
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunological aspects of melanoma].
    Sjögren H
    Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
    Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
    Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy for human malignant melanoma.
    Kopf AW
    South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
    Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
    Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
    Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of administering B.C.G. to patients with melanoma.
    Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
    Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract]   [Full Text] [Related]  

  • 12. [BCG-treatment of malignant melanoma].
    Borberg H
    Internist (Berl); 1975 Oct; 16(10):482-5. PubMed ID: 1107254
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunology of melanoma].
    Vanwijck R; Bernheim JL; Lejeune FJ
    Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 15. B.C.G. in malignant melanoma.
    Baker MA; Taub RN
    Lancet; 1973 May; 1(7812):1117-8. PubMed ID: 4122031
    [No Abstract]   [Full Text] [Related]  

  • 16. Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
    Vanwijck R; Bouillenne C; Malek-Mansour S
    Eur J Cancer (1965); 1975 Apr; 11(4):267-76. PubMed ID: 1079770
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 18. Progress of immunotherapy in the treatment of malignant melanoma.
    Ariyan S
    Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunotherapy of malignant melanomas].
    Macher E
    Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
    [No Abstract]   [Full Text] [Related]  

  • 20. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.